Seeking Alpha

Allergan (AGN) reports a successful Phase III trial of its treatment for overactive bladders....

Allergan (AGN) reports a successful Phase III trial of its treatment for overactive bladders. The company says that based on the results it has pushed forward with applications to the FDA and EU to expand the range of patients approved for the medication.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs